Market capitalization | $10.19m |
Enterprise Value | $35.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.89 |
P/S ratio (TTM) P/S ratio | 0.83 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 15.47% |
Revenue (TTM) Revenue | $12.24m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
1 Analyst has issued a forecast Biotricity Inc:
1 Analyst has issued a forecast Biotricity Inc:
Jun '24 |
+/-
%
|
||
Revenue | 12 12 |
15%
15%
|
|
Gross Profit | 8.80 8.80 |
44%
44%
|
|
EBITDA | -7.34 -7.34 |
43%
43%
|
EBIT (Operating Income) EBIT | -7.63 -7.63 |
42%
42%
|
Net Profit | -14 -14 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biotricity, Inc. is a medical technology company, which is focused on biometric data monitoring solutions. It also involves in delivering, remote monitoring solutions to the medical, healthcare, and consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. The firm’s FDA-approved Bioflux MCT technology, is comprised of a monitoring device and software components, which is made available to the market, in order to assess, establish and develop sales processes, and market dynamics. The company was founded by Waqaas Al-Siddiq and Peter McGoldrick on August 29, 2012 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Waqaas Al-Siddiq |
Employees | 55 |
Founded | 2012 |
Website | www.biotricity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.